IL177917A0 - Macrocyclic compounds as inhibitors of viral replication - Google Patents

Macrocyclic compounds as inhibitors of viral replication

Info

Publication number
IL177917A0
IL177917A0 IL177917A IL17791706A IL177917A0 IL 177917 A0 IL177917 A0 IL 177917A0 IL 177917 A IL177917 A IL 177917A IL 17791706 A IL17791706 A IL 17791706A IL 177917 A0 IL177917 A0 IL 177917A0
Authority
IL
Israel
Prior art keywords
inhibitors
viral replication
macrocyclic compounds
macrocyclic
compounds
Prior art date
Application number
IL177917A
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of IL177917A0 publication Critical patent/IL177917A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
IL177917A 2004-03-30 2006-09-06 Macrocyclic compounds as inhibitors of viral replication IL177917A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55816104P 2004-03-30 2004-03-30
US56241804P 2004-04-14 2004-04-14
US61238104P 2004-09-22 2004-09-22
US61246004P 2004-09-22 2004-09-22
PCT/US2005/010494 WO2005095403A2 (en) 2004-03-30 2005-03-29 Macrocyclic compounds as inhibitors of viral replication

Publications (1)

Publication Number Publication Date
IL177917A0 true IL177917A0 (en) 2006-12-31

Family

ID=35005653

Family Applications (1)

Application Number Title Priority Date Filing Date
IL177917A IL177917A0 (en) 2004-03-30 2006-09-06 Macrocyclic compounds as inhibitors of viral replication

Country Status (16)

Country Link
EP (1) EP1749007A2 (en)
JP (1) JP4950026B2 (en)
AP (1) AP2006003763A0 (en)
AR (1) AR050321A1 (en)
AU (1) AU2005228894B9 (en)
BR (1) BRPI0509467A (en)
CA (1) CA2560897C (en)
CU (1) CU23787B7 (en)
EA (1) EA012389B1 (en)
EC (1) ECSP066959A (en)
GE (1) GEP20104926B (en)
IL (1) IL177917A0 (en)
MA (1) MA28548B1 (en)
NO (1) NO20064933L (en)
NZ (1) NZ549697A (en)
WO (1) WO2005095403A2 (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2006020049A2 (en) 2004-07-15 2006-02-23 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2600367C (en) * 2005-03-08 2014-08-12 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI387603B (en) 2005-07-20 2013-03-01 Merck Sharp & Dohme Hcv ns3 protease inhibitors
GEP20105124B (en) 2005-07-25 2010-11-25 Array Biopharma Inc Novel macrocyclic inhibitors of hepatitis c virus replication
BRPI0614242A2 (en) * 2005-07-29 2011-03-15 Medivir Ab macrocyclic hepatitis c virus inhibitors, combination and pharmaceutical composition comprising them, as well as use and process for the preparation of said inhibitors
AR055395A1 (en) 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ569293A (en) 2005-12-23 2011-10-28 Zealand Pharma As Modified lysine-mimetic compounds
WO2008008776A2 (en) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
NZ574605A (en) 2006-07-13 2011-11-25 Achillion Pharmaceuticals Inc 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) * 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2357494T3 (en) * 2006-11-16 2011-04-27 Bristol-Myers Squibb Company MACROCYCLIC PEPTIDES AS INHIBITORS OF HEPATITIS C.
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL2468724T3 (en) 2006-12-21 2016-05-31 Zealand Pharma As Synthesis of pyrrolidine compounds
CA2679563A1 (en) * 2007-01-08 2008-07-17 Phenomix Corporation Macrocyclic hepatitis c protease inhibitors
WO2008096002A1 (en) * 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Hcv inhibiting macrocyclic phosphonates and amidophosphates
WO2008106130A2 (en) 2007-02-26 2008-09-04 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of hcv replication
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2177523A1 (en) 2007-05-03 2010-04-21 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
EP2162432A2 (en) 2007-06-29 2010-03-17 Gilead Sciences, Inc. Antiviral compounds
KR101596524B1 (en) 2007-06-29 2016-02-22 길리애드 사이언시즈, 인코포레이티드 Antiviral compound
US20090047252A1 (en) * 2007-06-29 2009-02-19 Gilead Sciences, Inc. Antiviral compounds
SE531698C2 (en) 2007-07-12 2009-07-07 Respiratorius Ab New bronchodilating a, b unsaturated amides
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
AU2008340261C1 (en) 2007-12-21 2015-12-10 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US9163061B2 (en) 2007-12-21 2015-10-20 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
DK2238142T3 (en) 2007-12-24 2012-10-08 Janssen R & D Ireland Macrocyclic indoles such as hepatitis C virus inhibitors
MX2010010660A (en) * 2008-04-11 2010-10-25 Hoffmann La Roche New ruthenium complexes as catalysts for metathesis reactions.
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5529120B2 (en) 2008-05-29 2014-06-25 ブリストル−マイヤーズ スクイブ カンパニー Hepatitis C virus inhibitor
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AU2009278075B2 (en) * 2008-08-07 2013-07-04 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (en) 2008-09-11 2010-04-30 Enanta Pharm Inc HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
UA103496C2 (en) 2008-09-17 2013-10-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Combination of hcv ns3 protease inhibitor with interferon and ribavirin
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2364309B1 (en) 2008-12-10 2014-10-01 Achillion Pharmaceuticals, Inc. New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2009329867B2 (en) 2008-12-23 2015-01-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
EA019295B1 (en) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Synthesis of purine nucleosides and process for preparing them
NZ617066A (en) 2008-12-23 2015-02-27 Gilead Pharmasset Llc Nucleoside analogs
EP2401272B1 (en) 2009-02-27 2017-01-11 Janssen Pharmaceuticals, Inc. Amorphous salt of a macrocyclic inhibitor of hcv
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
ES2446971T3 (en) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahydroisoquinolines substituted with aryl, heteroaryl, and heterocycle and their use
MX2011011907A (en) 2009-05-12 2012-01-20 Albany Molecular Res Inc 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4- tetrahydroisoquinoline and use thereof.
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
BR112012000287B8 (en) 2009-07-07 2021-05-25 Boehringer Ingelheim Int pharmaceutical composition for a hepatitis c viral protease inhibitor
AR077712A1 (en) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc SERINA PROTEASA MACROCICLICA INHIBITORS
WO2011038283A1 (en) * 2009-09-28 2011-03-31 Hoffmann-La Roche Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CN102843909A (en) 2010-01-25 2012-12-26 埃南塔制药公司 Hepatitis c virus inhibitors
AU2011235044A1 (en) 2010-03-31 2012-11-22 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
EP2552933A1 (en) 2010-03-31 2013-02-06 Gilead Pharmasset LLC Purine nucleoside phosphoramidate
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
AU2011329233A1 (en) 2010-11-15 2013-05-23 Abbvie Deutschland Gmbh & Co Kg NAMPT and ROCK inhibitors
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
PE20140039A1 (en) 2010-12-30 2014-03-01 Enanta Pharm Inc HEPATITIS C SERINE PROTEASE INHIBITORS BASED ON Phenanthridine Macrocyclics
TW201309690A (en) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
AU2012382373A1 (en) 2012-06-12 2014-12-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
MA37992B1 (en) 2012-10-19 2018-09-28 Bristol Myers Squibb Co Ns3 protease inhibitor compounds for use in the treatment of hepatitis c virus infection.
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2016515139A (en) 2013-03-14 2016-05-26 アキリオン ファーマシューティカルズ，インコーポレーテッド A new method for producing buckwheatprevir
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
EP2970192A1 (en) 2013-03-15 2016-01-20 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
WO2014145507A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
MX2016002185A (en) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Combination formulation of two antiviral compounds.
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2018202865A1 (en) 2017-05-05 2018-11-08 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022061A1 (en) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd INHIBITING PEPTIDES OF HEPATITIS C, A PHARMACEUTICAL COMPOSITION CONTAINING THEM, THE USE OF THE SAME TO PREPARE A PHARMACEUTICAL COMPOSITION, THE USE OF AN INTERMEDIATE PRODUCT FOR THE PREPARATION OF THESE PEPTIDES AND A PROCEDURE FOR THE PREPARATION OF ANOGRAPH .
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
WO2002060926A2 (en) * 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) * 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2369970A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2370396A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
DE60334205D1 (en) * 2002-05-20 2010-10-28 Bristol Myers Squibb Co Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
CA2540858C (en) * 2003-10-14 2009-12-08 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
JP4902361B2 (en) * 2004-01-30 2012-03-21 メディヴィル・アクチエボラーグ HCVNS-3 serine protease inhibitor

Also Published As

Publication number Publication date
AU2005228894A1 (en) 2005-10-13
AU2005228894B2 (en) 2011-08-25
CU20090209A7 (en) 2011-04-26
MA28548B1 (en) 2007-04-03
CA2560897A1 (en) 2005-10-13
JP4950026B2 (en) 2012-06-13
GEP20104926B (en) 2010-03-25
BRPI0509467A (en) 2007-09-11
EP1749007A2 (en) 2007-02-07
AU2005228894B9 (en) 2011-10-13
AP2006003763A0 (en) 2006-10-31
WO2005095403A3 (en) 2005-12-01
JP2007531749A (en) 2007-11-08
EA200601467A1 (en) 2007-06-29
CA2560897C (en) 2012-06-12
EA012389B1 (en) 2009-10-30
WO2005095403A2 (en) 2005-10-13
NO20064933L (en) 2006-12-15
ECSP066959A (en) 2006-12-20
NZ549697A (en) 2009-12-24
CU23787B7 (en) 2012-03-15
AR050321A1 (en) 2006-10-18

Similar Documents

Publication Publication Date Title
AP2006003763A0 (en) Macrocyclic compounds as inhibitors of viral replication
ZA200608798B (en) Macrocyclic compounds as inhibitors of viral replication
IL221361A0 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
IL240244A0 (en) Macrocyclic inhibitors of hepatitis c virus
AP2585A (en) Macrocyclic inhibitors of hepatitis C virus
AP2473A (en) Macrocyclic inhibitors of hepatitis C virus
SI1912997T1 (en) Macrocyclic inhibitors of hepatitis c virus
SI1919898T1 (en) Macrocyclic inhibitors of hepatitis c virus
PL1919904T3 (en) Macrocyclic inhibitors of hepatitis c virus
PL1913015T3 (en) Macrocyclic inhibitors of hepatitis c virus
PL1919899T3 (en) Macrocyclic inhibitors of hepatitis c virus
IL188281A0 (en) Macrocyclic inhibitors of hepatitis c virus
IL180738A0 (en) Inhibitors of hcv replication
AP2006003808A0 (en) Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
AP2009005053A0 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
ZA200700854B (en) Inhibitors of HCV replication
EP1776140A4 (en) Methods of inhibiting viral replication
ZA200800859B (en) Macrocyclic inhibitors of hepatitis C virus
ZA200800715B (en) Novel macrocyclic inhibitors of hepatitis C virus replication
ZA200800856B (en) Macrocyclic inhibitors of hepatitis C virus
ZA200800860B (en) Macrocyclic inhibitors of hepatitis C virus
AU2004903202A0 (en) Inhibition of Viral Replication Using Viperin
ZA200907644B (en) Novel macrocyclic inhibitors of hepatitis C virus replication